Navigation Links
SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR-NCI-EORTC International Conference
Date:10/17/2007

DUBLIN, Calif., Oct. 17 /PRNewswire-FirstCall/ -- SuperGen Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, today announced that multiple abstracts have been accepted for poster presentations at the AACR-NCI-EORTC International Conference from Oct. 22-26 at the Moscone Center in San Francisco.

The poster presentations will focus on data concerning many of SuperGen's current oncology programs including the lead clinical compound, MP470, and its ability to suppress the repair of double stranded DNA breaks following treatment with DNA-damaging agents.

In addition to the poster presentations listed below, data on SuperGen's hypomethylating agent, S110, will be presented by Dr. Peter A. Jones on Wednesday, Oct. 24 at 8:00 a.m. in Plenary Session 3: Epigenetic Targets.

SuperGen's schedule of presentations is as follows:

Poster

Date Time (PDT) Abstract # and Title Number/Session

Tuesday, 12:30 p.m.- # 1026 - MP470 #A173

Oct. 23 2:30 p.m. suppresses repair of

double-strand breaks Poster Session A

5:30 p.m.- following treatment

7:30 p.m. with DNA-damaging

agents

Wednesday, 12:30 p.m.- # 1038 - The #B140

Oct. 24 2:30 p.m. decitabine-derived

demethylating Poster Session B

5:30 p.m.- dinucleotide, S110

7:30 p.m. shows improved

activity due to

increased drug

delivery and

stability

Thursday, 12:30 p.m.- # 907 - Effect of #C200

Oct. 25 2:30 p.m. small molecule

inhibitors of JAK2 Poster Session C

5:30 p.m.- kinase on modulating

7:30 p.m. signaling cascades

downstream of

cytokine receptors

Thursday, 12:30 p.m.- # 985 - A small #C208

Oct. 25 2:30 p.m. molecule inhibitor of

Pim-1 kinase with Poster Session C

5:30 p.m.- activity in both

7:30 p.m. hematological and

solid tumor

malignancies

About SuperGen

Based in Dublin, Calif., SuperGen, Inc. is a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies. SuperGen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors. For more information about SuperGen, please visit http://www.supergen.com.

Forward-Looking Statements

This news release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that may cause actual results to differ materially from the results discussed in these statements. Factors that might cause the company's results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the ability to discover, develop and move target compounds into clinical development and other risks and uncertainties detailed from time to time in the company's filings with the Securities and Exchange Commission including its most recently filed Form 10-Q and 10-K. SuperGen, Inc. undertakes no duty to update any of these forward-looking statements to conform them to actual results.

Contacts

Timothy L. Enns Mary M. Vegh

SuperGen, Inc. SuperGen, Inc.

SVP, Corporate Communications Manager, Investor Relations

& Business Development Tel: (925) 560-2845

Tel: (925) 560-0100 E-mail: mary.vegh@supergen.com

E-mail: tenns@supergen.com


'/>"/>
SOURCE SuperGen Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Chennai AIDS Campaign Highlights The Social Neglect Faced By Victims
2. Benzene Slick In China Highlights Water Pollution
3. India To Highlight Its Scientific Achievements
4. Homecare Association Highlights Cost-Effectiveness of Medicare and Medicaid
5. India To Highlight The Potential Role Of Ayurveda In London
6. Study Highlights Appetite Regulation Pathway, New Hope for Weight Loss
7. Study Highlights How Bacteria Respond To Changes In Environment
8. Drug Action Week to Highlight Effects of Alcohol
9. Clinton, Gates Highlight Treatment, Discrimination of AIDS
10. Highlights from World Transplant Congress
11. Latest IPCC Report Highlights Need for Integrated Climate/human Behavior Models
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and ... their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took ... the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... June ... about the dangers associated with chronic pain and the benefits of holistic treatments, ... individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of ... AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
(Date:6/23/2016)... , June 23, 2016 , ... on Thursday, July 7, 2016 , , , , LOCATION: ... , , , , EXPERT PANELISTS:  , , , ... Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and ... The global pharmaceutical industry is witnessing an exceptional era. ...
(Date:6/23/2016)... June 23, 2016 The vast majority of ... dialysis facility.  Treatments are usually 3 times a week, ... visit, including travel time, equipment preparation and wait time. ... especially grueling for patients who are elderly and frail.  ... nursing and rehabilitation centers for some duration of time. ...
Breaking Medicine Technology: